Genie Fertility Secures $1.22 Million for Uterus Health Test

• Genie Fertility, which was co-founded by Imperial College graduate Dr Andreas Hadjimitsis, raised $1.22 million
• The capital will be used to develop a non-invasive screening test to evaluate the health of the uterus and assist fertility treatment

Genie Fertility, a firm co-founded by Imperial College graduate Dr Andreas Hadjimitsis and Anoushka Menon, has secured $1.22 million (£908,000) of pre-seed investment from European and US investors.

The money will be used to develop a non-invasive test to evaluate uterine health and complement fertility treatment.

Uterine health is currently evaluated mainly by biopsy, an expensive invasive procedure that takes tissue from a small sample area and is not very accurate.

Genie Fertility examines menstrual blood for molecular markers associated with reproductive health through a machine learning platform to determine significant indicators.

Dr Andreas, Genie Fertility's Chief Technology Officer, explains there is limited data and knowledge about women's reproductive health because the uterus is inaccessible.

Menstrual blood, which captures the total monthly sloughing of the uterine lining, includes information not present in routine blood tests, a promise that has remained largely untapped in research.

The test's first use is for women having in vitro fertilisation (IVF), providing information about the health of the uterus to assist clinicians in enhancing the chances of conception.

Dr Andreas said IVF is the usual infertility treatment, but it does not work 73 percent of the time, and much attention has been given previously to sperm, egg, and embryo quality instead of the uterus.

Clinical trials started in March 2025, with patients donating menstrual blood samples, sometimes multiple times, to facilitate longitudinal studies.

The new funding will allow a nine-month study monitoring pregnancy outcomes according to the markers that Genie's machine learning model has identified.

The platform already has analyzed information from more than 200,000 fertility patients, and the study may find additional biomarkers to guide the construction of future diagnostic tests and treatments for ailments like polycystic ovary syndrome, endometriosis, and perimenopause.

Dr Andreas, who gained his PhD in Imperial's Department of Bioengineering studying 3D printing biomaterials for diagnostics, used his academic background and past experience working with synthetic biology firm CorNatural and US venture capital advisory positions to create the test.

There, he crossed paths with co-founder Anoushka Menon, today CEO of Genie Fertility, who had majored in genetics at Cambridge University and had worked previously in reproductive health. Together, they brought science know-how and lived experience to bridge gaps in fertility care.

Genie Fertility has also enjoyed continued backing from Imperial's Enterprise Lab, such as the Venture Mentoring programme, which advises on recruitment, regulation issues, testing structure, and fundraising.

Olivia Brown, Incubation Services Manager at the Enterprise Lab, highlighted the importance of mentorship in a startup's early life. The programme has mentored startups which have risen over £192 million in investment thus far.